Business
Telo Genomics Presents Genomic Profiles of Peripheral Blood Minimal Residual Disease Cells at the 67th American Society of Hematology Meeting
Toronto, Ontario--(Newsfile Corp. - December 11, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB...
About this update from Telo Genomics Corp.
[{"type":"text","content":"Telo Genomics Presents Genomic Profiles of Peripheral Blood Minimal Residual Disease Cells at the 67th American Society of Hematology MeetingToronto, Ontario--(Newsfile Corp. - December 11, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the \"Company\" or \"Telo\") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announced that the company highlighted its approach to Multiple Myeloma (MM) Minimal Residual Disease (MRD) testing with a poster presentation during the 67th American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. The poster presentation describes the initial clinical results of a new MRD evaluation that combines the enumeration of individual MM Circulating Tumor Cells (CTCs) from peripheral blood with the TeloView® 3D telomere profiling platform. Telo demonstrated that this approach consistently performs at a 1 in 10^7 limit of detection (finding one myeloma cell among 10 million blood cells) at different stages of the disease. Furthermore, TeloView® has identified distinct clusters of 3D genome profiles that characterize groups of individual patients and correlate to known patterns of high/low mutation rates. Larger studies are underway to validate the predictive power of these MRD profiles in determining risk of relapses, similar to the prognostic TeloView models for newly diagnosed MM and smoldering multiple myeloma.The abstract titled \"Novel method of minimal residual disease testing in myeloma: liquid biopsies to enumerate and 3D telomere-profile circulating tumor cells\", was presented by Dr. Yulia Shifrin, Laboratory Director of Telo Genomics. The abstract has also been published in the conference journal Blood, and the presentation poster is available on the Company website. \"This method provides functional, biological information about the residual disease cells themselves, offering insights into progression risk beyond cell counts,\" said Dr. Sabine Mai, co-founder and interim CEO of Telo Genomics. \"At the same time, evaluating CTCs from peripheral blood reduces reliance on repeated bone marrow procedures and makes continuous monitoring far more feasible.\"About MRD Assessment Minimal Residual Disease (\"MRD\") is defined as the small number of cancer cells that remain in the body after treatment,...